This device exploits antibody-coated magnetic particles targeting EpCAM to detect and quantify circulating tumor cells (CTCs) of epithelial origin in the whole blood of patients with metastatic breast cancer, prostate cancer, and colorectal cancer [168,194]. The gene discussed is EPCAM; the disease is neoplasm.